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Abstract
Background: Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts
have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are
tyrosine kinase inhibitors such as imatinib.
Case presentation: Here, we discuss the relevance of previously published cases and add another well-
characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase
inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome
positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the
possibility of dasatinib itself causing PH after long-term therapy and turn specialist’s attention to this possible
severe side effect.
At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding
haemodynamics are missing.
Conclusion: We therefore recommend systematic screening of dasatinib-treated patients for pulmonary
hypertension and subsequent collection of haemodynamic data.
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Background
Pulmonary hypertension (PH) is a severe and progres-
sive, mainly vasoproliferative disease characterised by
increased pulmonary artery pressure and vascular resis-
tance eventually leading to right heart failure and death
[1]. Different drugs have been identified to be causative
of PH such as anorectic drugs which gained notoriety in
the 1970s [2].
Dasatinib is a multi tyrosine kinase inhibitor approved
for first and second line therapy of chronic myeloic leu-
kaemia (CML) and Philadelphia chromosome positive
acute lymphocytic leukaemia [3,4].
During the last months there have been two reports
connecting dasatinib with the development of PAH
[5,6]. Alarmingly, another patient was referred to our
centre presenting with severe pre-capillary PH under
dasatinib therapy.
H e r e ,w er e p o r to nt h i sc a s ea n dw o u l dl i k et ot u r n
attention to this possible severe side effect of dasatinib.
Case presentation
A 70-year old male with chronic phase CML diagnosed
in 1996 was changed to dasatinib therapy due to subse-
quent haematological progress under hydroxyurea com-
bined with interferon alpha (1996-2002) and imatinib
(2002-2004: 400 mg/day, 2004-2005: 800 mg/d). Dasati-
nib treatment with a dose of 70 mg bid was applied for
32 months. Side effects during this period were minor
as the medication was generally tolerated well.
However, suddenly the patient developed tachy-dyspnea
(25/min), transsudative, non-malignant pleural effusions
(glucose 116 mg/dl; lactate dehydrogenase 188 IU/ml of
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protein content of effusions 31 g/l, serum protein content
67 g/l) and fatigue increasing within a few weeks.
Echocardiography showed highly increased right ven-
tricular systolic pressure (RVSP) of 73 mm Hg. Invasive
haemodynamic evaluation confirmed severe pre-capillary
PH with consecutive right heart failure (details on prog-
nostic factors and haemodynamics listed in Table 1).
Clinically, the patient was assigned to WHO/NYHA
functional class IV.
As other underlying pathophysiological reasons were
ruled out by serological tests, chest CT, scintigraphy of the
lung and abdominal ultrasound, dasatinib was consequently
discontinued. Normal wedge pressures at right heart cathe-
terisation also excluded tyrosine kinase inhibitor-induced
cardiomyopathy or other left heart diseases as possible
underlying pathologies.
After discontinuation of dasatinib medication low-dose
PAH-specific therapy with vasodilative phosphodiester-
ase-V inhibitor sildenafil (3 × 20 mg) was initiated.
Acute symptoms relieved within days.
During the following 10 months prognostic para-
meters such as the N-terminal fragment of pro brain-
natriuretic peptide (NT-proBNP), 6-minute walking dis-
tance (6MWD), RVSP, pulmonary artery mean pressure
(PAPmean) and pulmonary vascular resistance (PVR)
improved significantly (see Table 1). Additionally, the
patient’s subjective well-being advanced decisively which
was also reflected by a functional class improvement to
NYHA II (Figure 1).
Does dasatinib itself trigger pre-capillary PH?
Pulmonary complications of dasatinib therapy have been
reported ranging from pleural effusions to lung parench-
ymal affections [7]. In particular, pleural effusions
caused by dasatinib, which are mostly exsudative due to
clonal expansion of natural killer T cells, are well
recognised and have been documented in various stu-
dies [3,7,8]. In addition to the EMEA data set [3], in a
retrospective analysis of 138 patients receiving dasatinib
in once or twice daily treatment schedules, pleural effu-
sions of any grade were detected in 35% of the complete
study population comprising chronic phase, accelerated
phase and blast crisis [8].
Statistically significant, dose-dependent increase in
RVSP was reported in a subgroup of 18 patients and
dasatinib cessation led to normalisation of RVSP in 10
patients [8]. Dyspnoea, nausea, fatigue and oedema -
unspecific yet classical symptoms found in PH - are
among the most frequently observed unwanted dasatinib
effects. Up to now, the extent of dasatinib-associated
pre-capillary PH in contribution to these symptoms
remains illusive since data regarding haemodynamics are
lacking. However, all three detailed cases with dasatinib-
related pre-capillary PH developed after a 2-year period
of treatment (Figure 1C).
Our findings in combination with the two other pub-
lished cases suggest a yet unknown association of pre-
capillary PH with dasatinib [9]. Therefore, our patient
was categorised into Dana Point class 1.3 that resembles
drug-induced pulmonary arterial hypertension (PAH,
[10]). Dana Point I represents the only class where
PAH-specific drugs are labelled for. Hence PAH-specific
therapy with low-dose sildenafil was started.
Dana Point class V, on the other side, combines all
multifactorial or uncertain causes of PH and it explicitly
includes chronic myeloproliferative diseases. Neverthe-
less, in this case connection of PH with myeloprolifera-
tive disease is also unlikely since, firstly, the CML was
stable under dasatinib therapy for almost three years
without acceleration until the end of dasatinib therapy.
Secondly, a recent report showed a preferential associa-
tion of myeloproliferative disease-associated PH with
chronic thromboembolism [11], which was ruled out in
our patient by CT scans and V/Q scintigraphy. In such
case the use of sildenafil would have been off-label.
Taking into consideration that pleural effusions are
found rarely in pre-capillary pulmonary hypertension
another differential diagnosis has to be mentioned: pul-
monary veno-occlusive disease (PVOD). PVOD, again,
seems to be unlikely since it typically presents as non-
responsive PH [12]. However, symptoms and RVSP of
our patient rapidly improved after discontinuation of
dasatinib and initiation of sildenafil therapy. Addition-
ally, typical signs of PVOD such as ground glass opacity
and septal thickening in CT scans or crackles and club-
bing on examination [10] were absent in the presented
case.
Most interestingly, although dasatinib also inhibits the
platelet-derived growth factor receptor (PDGFR) path-
w a yt h e r em a yb eac o n t r a r ye f f e c to np r o l i f e r a t i v e
Table 1 Haemodynamic and prognostic data
Time of presentation
(/w dasatinib)
Time course under
sildenafil (w/o dasatinib)
Month: 0+ 1 + 3 + 5 + 7
RVSP [mm Hg] 73 51 - 17 -
PAPmean [mm Hg] 52 - - - 40
PVR [dyn*s/cm
-5] 1250 - - - 356
CO [l/min] 1.7 - - - 4.7
HR [/min] 105 - - - 85
proBNP [ng/l] 27055 3037 1334 2076 -
6MWD [m] 0 308 458 - -
WHO/NYHA FC IV II I/II II II
RVSP: right ventricular systolic pressure; PAPmean: mean pulmonary artery
pressure; PVR: pulmonary vascular resistance; CO: cardiac output; HR: heart
rate; proBNP: brain natriuretic peptide propeptide; 6MWD: 6-minute walk
distance; WHO/NYHA FC: World Health Organization/New York Heart
Association functional class.
Hennigs et al. BMC Pulmonary Medicine 2011, 11:30
http://www.biomedcentral.com/1471-2466/11/30
Page 2 of 4aspects of PAH compared to imatinib which has been
shown to be an effective treatment improving PAH and
animal survival as well as reversing pulmonary remodel-
ling in rodent model systems, a series of case reports
and a phase II trial [13-18]. Hence, a prospective rando-
mised safety and efficacy trial is currently ongoing
(IMPRES, ClinicalTrials.gov: NCT00902174).
As key mechanisms, imatinib reversed overexpression
and increased phosphorylation of PDGFRb in pulmon-
ary arteries from rat models of pulmonary hypertension,
inhibited PDGFR-related ERK1/2 activation in lungs of
these animals thereby suppressing rat pulmonary artery
smooth muscle cell (PA-SMC) proliferation and indu-
cing PA-SMC apoptosis [13].
While dasatinib inhibits Bcr-Abl at significantly lower
inhibitory concentrations (IC50) as compared to imati-
nib, its effect on c-kit and PDGFR are rather similar. In
addition, however, and different from imatinib, dasatinib
also inhibits the SRC family of kinases [19]. Whether
this aspect of the compound is causally related to PH
development remains unclear.
Conclusion
There are emerging data that dasatinib could trigger drug-
associated pre-capillary pulmonary hypertension. We
therefore recommend the systematic screening and collec-
tion of haemodynamic data of dasatinib-treated patients.
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Figure 1 Haemodynamics and prognosis factors of dasatinib-associated PAH. Time courses of haemodynamics (Right ventricular systolic
pressure, RVSP and mean pulmonary artery pressure, PAPmean, A) as well as exercise capacity (6MWD), WHO functional class and concentration
of NT-proBNP (B) of the Hamburg patient are shown. Dashed horizontal line in (B) represents upper normal limit of NT-proBNP concentration
(<197 ng/l). RVSP time courses of all three dasatinib-associated PH cases characterised so far are shown in (C). Vertical dashed line represents
time of discontinuation of dasatinib treatment.
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